Nasdaq, Inc. (NDAQ) Adds Moderna to Nasdaq-100 on Oct. 9, 2026

Nasdaq announced Moderna will replace Warner Bros. Discovery on the Nasdaq 100 index, effective October 9. Moderna's shares have risen over sixfold this year, valuing the company at about $75 billion. Warner Bros. Discovery is also set to be removed from other major indexes due to its upcoming merger with Paramount Skydance.

Moderna will join the Nasdaq-100 index on October 9, replacing Warner Bros. Discovery, which is being acquired by Paramount-Skydance. Moderna's shares rose 0.6% in after-hours trading. The change is due to the upcoming acquisition of Warner Bros. Discovery.

Northwestern University won a court ruling to strike Moderna Inc.'s defense in a patent infringement case. The judge ruled that Moderna's claim of government license protection is inconsistent with the Bayh-Dole Act. This case involves patents covering vaccine-delivery technology.

Moderna (MRNA) shares are volatile after Citi downgraded the stock to Sell with an $80 price target, citing valuation concerns. Despite this, MRNA remains near its 52-week high of $208.90, up 223% since August. The company announced leadership changes and expanded its vaccine portfolio. Analysts are divided, with 15 of 24 still rating it a Buy.

Moderna (MRNA) stock dropped over 5% after Citi analyst Geoff Meacham suggested selling due to an 'outsized run' since August 19, citing potential profit-taking and limited short-term upside.

Moderna (MRNA) and Merck (MRK) reported that their cancer vaccine reduced melanoma recurrence in a study, according to the companies. Experts called the results a 'landmark win' with potential for significant sales. The companies plan further steps, which could impact their stock prices.